Matinas BioPharma Holdings (MTNB) Enterprise Value (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Enterprise Value of -$2.4 million for Q1 2026, up 64.9% year-over-year from -$1.5 million in Q1 2025, and up 39.54% quarter-over-quarter from -$4.0 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Enterprise Value (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Enterprise Value data on file, last reported at -$2.4 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$2.4 million, up 64.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 million (up 64.9% YoY), and the FY2025 annual result was -$4.0 million, up 44.79% from the prior year.
- Enterprise Value improved to -$2.4 million in Q1 2026 per MTNB's latest filing, from -$4.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$1.1 million in Q1 2024 and troughed at -$43.8 million in Q1 2022.
- A 5-year average of -$13.5 million and a median of -$7.0 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value surged 86.79% in 2023, then plunged 522.12% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$6.9 million in 2022, then slumped by 99.94% to -$13.8 million in 2023, then jumped by 46.69% to -$7.3 million in 2024, then jumped by 44.79% to -$4.0 million in 2025, then jumped by 39.54% to -$2.4 million in 2026.
- Business Quant data shows MTNB's Enterprise Value at -$2.4 million in Q1 2026, -$4.0 million in Q4 2025, and -$5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | -2.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.45 Mn |
| Dec 31, 2025 | -4.05 Mn |
| Sep 30, 2025 | -5.49 Mn |
| Jun 30, 2025 | -6.58 Mn |
| Mar 31, 2025 | -6.97 Mn |
| Dec 31, 2024 | -7.33 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -14.31 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | -13.76 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Jun 30, 2023 | -22.51 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | -6.88 Mn |
| Sep 30, 2022 | -33.05 Mn |
| Jun 30, 2022 | -38.50 Mn |
| Mar 31, 2022 | -43.83 Mn |
| Dec 31, 2021 | -21.08 Mn |
| Sep 30, 2021 | -53.83 Mn |
| Jun 30, 2021 | -59.84 Mn |